Pyrimethamine
Familial Amyotrophic Lateral Sclerosis
Weill Medical College of Cornell UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Familial Amyotrophic Lateral Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ISIS-333611 Ionis Pharmaceuticals, Inc. | Phase 1 | CC |
BETAMETHASONE Edward Kasaraskis | Early Phase 1 | CC |
Same molecule, other indications
Pyrimethamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →